The introduction and clinical implementation of T cell-directed immunomodulators blocking immune checkpoints CTLA-4, programmed cell death-ligand 1 (PD-L1) and PD-1 have rejuvenated the field of tumor immunology and revolutionized cancer treatment far beyond their impressive clinical activity. The gene discussed is CD274; the disease is neoplasm.